May 2015 Corporate Presentation
Melbourne, May 1, 2015 AEST (ABN Newswire) - Compumedics Limited (
ASX:CMP) Up-dated May 2015 Corporate Presentation including an Investor overview.
Investor Overview
- Core business: returned to growth.
- Neurology growth opportunity: New market for CMP. We have the leading brain source localisation software.
* Asian EEG - largest segment of $886.8 m brain monitoring device market
* Asian EEG - 2013 $81.8m PA to 2018 $133.0m by 2018, CAGR: 10.40% (1)
- Trend towards Home Sleep Testing (HST) - CMP well positioned - growing market (2)(3)
- eHealth: Moving Compumedics' proprietary technology to the cloud. $10m of contracts already won.
- Spin offs/strategic decisions to unlock significant value for shareholders
- FY15 guidance: $33m sales, revenue growth >10%, EBITDA $3.5-4m, NPAT $1.8-$2m.
To view the corporate presentation, please visit:
http://media.abnnewswire.net/media/en/docs/ASX-CMP-422735.pdf
About Compumedics Limited
Compumedics Limited (ASX:CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including Americas; Australia and Asia Pacific; and Europe and the Middle East.
Executive Chairman, Dr David Burton, founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised Sleep Clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets. Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards and accolades including Australia's exporter of the year and has been recognised as a Top 100 Innovator by both German and Australian Governments.
Follow Compumedics on Twitter at @Compumedics
| ||
|
